651 filings
Page 3 of 33
8-K
pz7qk91l
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
424B5
gfcq1et6tl sg
9 May 23
Prospectus supplement for primary offering
2:41pm
EFFECT
vu95gz2v3e21
8 May 23
Notice of effectiveness
12:15am
CORRESP
vslch w6yd3z3
3 May 23
Correspondence with SEC
12:00am
DEFA14A
uweexk1i hgtmmb4cm
28 Apr 23
Additional proxy soliciting materials
4:21pm
8-K
122zusqedpmtbm
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
UPLOAD
x4gw6u
23 Mar 23
Letter from SEC
12:00am
8-K
h28ztw72ysz2wq1mr kp
15 Mar 23
Vaxart Provides Business Update and Full Year 2022 Financial Results
7:58pm
8-K
01m5w0vsc bstrbydm5
19 Dec 22
Vaxart Names Phillip Lee as Chief Financial Officer
5:25pm
8-K
m41x3
6 Dec 22
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
4:21pm
8-K
ldk8xj hcjybfwcrrue6
8 Nov 22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4:10pm
S-8
90jsn2j5pj 9slr8ck
21 Oct 22
Registration of securities for employees
9:04pm
8-K
zoqlo hmv3vnm
1 Sep 22
Regulation FD Disclosure
7:05am
8-K
17hpy
25 Aug 22
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
4:09pm